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Background: The primary aim of this pilot study was to determine the feasibility and safety of an adoptive transfer
and in vivo expansion of human haploidentical γδ T lymphocytes.
Methods: Patients with advanced haematological malignancies who are not eligible for allogeneic transplantation
received peripheral blood mononuclear cells from half-matched family donors. For that, a single unstimulated
leukapheresis product was incubated with both the anti-CD4 and anti-CD8 antibodies conjugated to paramagnetic
particles. The depletion procedure was performed on a fully automated CliniMACS® device according to the
manufacturer’s instructions. On average, patients received 2.17 × 106/kg (range 0.9-3.48) γδ T cells with <1% CD4-
or CD8-positive cells remaining in the product. All patients received prior lymphopenia-inducing chemotherapy
(fludarabine 20-25 mg/m2 day -6 until day -2 and cyclophosphamide 30-60 mg/kg day -6 and -5) and were treated
with 4 mg zoledronate on day 0 and 1.0x106 IU/m2 IL-2 on day +1 until day +6 for the induction of γδ T cell
proliferation in vivo.
Results: This resulted in a marked in vivo expansion of donor γδ T cells and, to a lower extent, natural killer cells
and double-negative αβ T cells (mean 68-fold, eight-fold, and eight-fold, respectively). Proliferation peaked by
around day +8 and donor cells persisted up to 28 days. Although refractory to all prior therapies, three out of four
patients achieved a complete remission, which lasted for 8 months in a patient with plasma cell leukaemia. One
patient died from an infection 6 weeks after treatment.
Conclusion: This pilot study shows that adoptive transfer and in vivo expansion of haploidentical γδ T lymphocytes
is feasible and suggests a potential role of these cells in the treatment of haematological diseases.
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For many patients with refractory haematological malig-
nancies, allogeneic stem cell transplantation (SCT) re-
mains the only chance of a cure. However, due to its high
toxicity, a significant number of patients are not eligible
for this approach.
The anti-tumour activity of allogeneic SCT is primarily
mediated by an immunological graft-versus-tumour effect
mediated by donor lymphocytes. Ruggeri et al. demon-
strated that a KIR ligand mismatch enhanced the donor* Correspondence: martin.wilhelm@klinikum-nuernberg.de
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unless otherwise stated.natural killer (NK) cell alloreactivity in haploidentical
transplantations, through a “missing self-recognition” in
patients with AML [1]. Furthermore, Miller et al. de-
scribed a successful adoptive transfer and in vivo expan-
sion of haploidentical NK cells by interleukin 2 (IL-2) in a
non-transplantation setting [2]. The major advantages of
immunotherapy with innate lymphocytes compared with
MHC-restricted αβ T cells are that they can kill tumour
cells without prior exposure and do not induce graft-
versus-host disease (GVHD) [3].
However, currently used approaches with allogeneic
innate lymphocytes are solely focused on NK cells and
underscore the powerful anti-tumour activity of γδ T
cells [2,4,5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gens, but are also capable of exerting significant MHC-
unrestricted activity against a broad spectrum of tumour
cells in vitro, especially haematological neoplasia [6,7].
Although their mechanism of target cell recognition is
not fully understood, it is known that Vγ9Vδ2 T cells,
which represent the vast majority of human circulating
γδ T cells, recognise naturally occurring and synthetic
phosphoantigens (i.e., aminobisphosphonates such as
pamidronate or zoledronate) [8,9].
In two previous trials (phase I/II) in patients with re-
lapsed/refractory malignancies, we demonstrated that a
combination of pamidronate or zoledronate and low-
dose IL-2 not only induced the selective activation and
proliferation of Vγ9Vδ2 T cells in vivo, but could also be
accompanied by anti-tumour activity [10,11]. However, a
general drawback of autologous γδ T cell-mediated
tumour-immunotherapy is the frequent impaired func-
tion of γδ T cells in up to 50-70% of cancer patients
[7,10,12].
Here, we present for the first time data showing that
the adoptive transfer of haploidentical γδ T cells is a
feasible and safe method for the in vivo expansion of
these innate immune effector cells in patients with re-
fractory haematological malignancies.
Methods and materials
Patients and treatment protocol
In this pilot study, four subsequent patients with
advanced refractory haematological malignancies (one
T-NHL, one AML, one secondary plasma cell leukaemia,
and one multiple myeloma) who were not eligible for
allogeneic transplantation were included. HLA typing of
the patients and their haploidentical family members
were performed to select a donor with an HLA mis-
match, which was detectable by FACS analysis with an
HLA-specific antibody. Infusion of a CD4/CD8 T cell-
depleted leukapheresis product (donor innate lymphocyte
infusion = DILI) and Hi-Cy/Flu as prior immunosuppres-
sive chemotherapy (fludarabine 25 mg/m2 day -6 until
day -2 and cyclophosphamide 60 mg/kg day -6 and -5)
were performed as described [2,4,5]. However, according
to the general conditions and/or prior therapies, the dose
of cyclophosphamide was reduced by 50% in patients 1
and 2, and both cyclophosphamide/fludarabine by 25% in
patients 3 and 4. All patients received intravenous (i.v.)
zoledronate at a dose of 4 mg after DILI infusion on day
0 and subcutaneous (s.c.) 1.0x106 IU/m2 IL-2 on day +1
until day +6.
The collection of PBMCs and depletion of CD4+ and
CD8+ cells were performed as previously described [13].
In brief, a single unstimulated leukapheresis was per-
formed from family donors using a Cobe Spectra (Gambro
BCT, Planegg-Martinsried, Germany). The cells wereincubated with anti-CD4 and anti-CD8 antibodies conju-
gated to paramagnetic particles and then processed with
the fully automated device CliniMACS® Plus (Miltenyi
Biotec) using the program “Depletion 2.1”, according to
the manufacturer’s instructions.
This pilot study was approved by the institutional re-
view board and all participants gave written informed
consent.
Flow cytometric analysis
Leukapheresis products and patient samples were analysed
using CD3, CD4, CD8, CD14, CD15, CD16 + CD56,
CD19, TCRαβ, and TCRγδ fluorochrome-labelled anti-
bodies by four-colour FACS analysis (Epics XL/FC500,
Beckman Coulter). In vivo expansion of HLA-mismatched
donor lymphocytes was followed by FACS-based chime-
rism analysis with prior tested specific antibodies every
other day.
Results and discussion
The four subsequent patients with advanced refractory
haematological malignancies received their leukapheresis
product from unstimulated haploidentical family donors
in the lymphopenic phase after prior cyclophosphamide/
fludarabine treatment (Figure 1E). Preservation of the
function of γδ T cells was tested after separation by
proliferation and cytotoxicity assays against different tar-
gets (data not shown) [13]. The product contained 2.17 ×
106/kg (range 0.9-3.48) γδ T cells and 8.87 × 106/kg
(range 1.54-18.82) NK cells (Table 1). Although a signifi-
cant number of αβ T cells remained in the transplant
(0.7-2.06 × 106/kg), this fraction was primarily composed
of CD4- and CD8-negative cells (Table 1). Double-
negative (DN) T cells have been shown to possess the
ability to regulate immune responses in transplant rejec-
tion, tumour immunity, infectious diseases, and GVHD
[14-16]. Therefore, our separation products, engineered
by CD4/CD8 depletion, were supplemented by a subpop-
ulation of αβ T cells, which have further interesting cap-
abilities regarding the prevention of GVHD and tumour
immunity.
Engraftment and expansion of donor cells
Our prior trials in the autologous setting clearly showed
that the expansion of γδ T cells in vivo was a prerequis-
ite for tumour regression, since only patients with sig-
nificant in vivo proliferation of γδ T cells exhibited a
tumour response [10]. Therefore, one major goal of our
study was to investigate the feasibility and tolerability of
selective in vivo expansion of the adoptively transferred
haploidentical γδ T cells. For that, patients received a
phosphoantigen (4 mg zoledronate) and low-dose IL-2
(1-2 × 106 IE) s.c. for 6 days, starting on day 1 after
transfusion. The results showed that a transient but
Figure 1 (See legend on next page.)
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Figure 1 Treatment protocol and cell engraftment. Number of donor natural killer (NK) cells (A), γδ T cells (B), and αβ T cells (C) per
microlitre. The individual symbols represent patient samples obtained at the different time points. Peripheral blood lymphocytes were analysed
using fluorochrome-labelled TCRαβ, TCRγδ, CD56, and donor-specific HLA antibodies by four-colour FACS analysis. (D) Fold increase is calculated
as the ratio of the cell number per microlitre on day 8 to the initial value. (E) Treatment and adoptive transfer of donor innate lymphocytes in
patient 3, who had a refractory plasma cell leukaemia. In vivo expansion of HLA-B8+ haploidentical γδ T cells within the HLA-B8- recipient was
followed by FACS-based chimerism analysis. Right upper quadrant shows the percentage of donor γδ T cells over time.
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extent, of donor NK cells and DN αβ T cells occurred in
these patients (Figure 1). In all patients, proliferation
peaked by around day +8, while on day +15, in three out
of four patients there were no detectable donor cells, con-
current with the regeneration of recipient cells. The mean
number of γδ T cells, NK cells and DN αβ T cells was ap-
proximately 43 cells/μL, 9 cells/μL, and 6 cells/μL, which
represented a 68-fold, an eight-fold, and an eight-fold ex-
pansion, respectively. However, in patient 4, who showed
the most profound γδ T cell expansion, cells were detect-
able for as long as 28 days after transfusion. Due to the
underlying disease and multiple prior therapies including
autologous stem cell transplantation, patient 4 was se-
verely immunosuppressed, suggesting that the degree of
immunosuppression may be a determinant in the duration
of engraftment. Miller et al. have already shown that the
survival of haploidentical lymphocytes is dependent on
the extent of prior immunosuppression by comparing
low- and high-intensity regimens [2].Table 1 Patient characteristics and cell products
Patient 1 Patient 2 Patient 3 Patient 4
Patient characteristics
Age/sex 44/m 69/m 70/m 65/m
Disease T-NHL AML SPL MM
No. prior regimens 4 1 3 7
Donor sister son daughter son
Best response CR CR CR n.e.
a/c GVHD -/- -/n.e. -/- -/n.e.
Outcome R/5 mo R/2 mo R/8 mo e.d./6 wk
Cell dose (106/kg)
γδ T cells 2.98 0.99 1.23 3.48
NK cells 18.82 12.85 2.26 1.54
αβ T cells 1.74 1.14 2.06 0.70
CD4+ T cells 0.01 0.03 0.02 0.006
CD8+ T cells 0.04 0.06 0.004 0.02
Total 23.59 15.07 5.57 5.75
KIR-mm + - + +
T-NHL indicates T-cell Non-Hodgkin-Lymphoma; AML, Acute Myeloid
Leukaemia; SPL, Secondary Plasma Cell Leukaemia; MM, Multiple Myeloma;
a/c GVHD, acute/chronic graft-versus-host disease; R, relapse; n.e., not
evaluable; e.d., early death; KIR-mm, KIR ligand incompatibility in the
graft-versus-host direction.Side effects
The duration of neutropenia (< 500/μl) was 20 (range
11-33) days. Although it has not been shown that γδ T
cells recognise alloantigens, potential hazardous effects
of in vivo stimulated mismatched γδ T cells was of major
concern. Although patient 4 died from severe septicae-
mia (Staphylococcus epidermidis + Enterobacter faecium)
on day +45, with his haematopoiesis already recovered,
none of the patients showed any signs of acute or
chronic GVHD nor organ injury (Table 1).Efficacy
Three out of four patients achieved a complete remission,
which lasted between 2 and 8 months. For example, pa-
tient 3, who suffered from secondary plasma cell leukae-
mia and did not respond to 3 different regimens including
autologous stem cell transplantation, also achieved a strin-
gent complete remission (Figure 1).
It cannot be excluded, that the Flu/Cy regimen given
prior cell transfusion for lymphopenia induction, in-
duced a significant tumour regression in the patients.
However, refractoriness to all other prior treatment ap-
proaches and the kind of underlying diseases argues
against this assumption. Due to the small patient num-
ber, we were not able to differentiate which cell popula-
tion was the main contributor for remission induction.
Figure 1 shows the expansion of NK cells, αβ T cells and
γδ T cells. It is very likely that the αβ T cell population
consists at least in part of double-negative (classically
Va24 + CD3+) invariant natural killer T (iNKT) cells.
Given the known efficacy of iNKT cells against lymphoid
tumour cells, it is possible that besides αβ T cells and
“classical” NK cells, this subpopulation contributed to
the anti-tumour effect, particularly in the cases of
lymphoid malignancies [14,17-20].Conclusion
This pilot study showed for the first time that infusion
of haploidentical γδ T cells is feasible and the adminis-
tration of phosphoantigens and low-dose IL-2 induces a
significant proliferation of donor γδ T cells in vivo
[10,11]. In addition, this clinical trial provides the first
evidence that selective stimulation of allogeneic γδ T
cells can be accompanied by anti-tumour activity in vivo
without inducing GVHD.
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